Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRVA Stock Forecast 2026-2027
$23.43
Current Price
$2.95B
Market Cap
Buy 18
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to PRVA Price Targets
+70.7%
To High Target of $40.00
+32.3%
To Median Target of $31.00
+2.4%
To Low Target of $24.00
PRVA Price Momentum
+8.3%
1 Week Change
+0.8%
1 Month Change
+3.4%
1 Year Change
-1.2%
Year-to-Date Change
-11.6%
From 52W High of $26.51
+24.8%
From 52W Low of $18.77
📊 TOP ANALYST CALLS
Did PRVA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Privia Health is one of their latest high-conviction picks.
Latest PRVA Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, PRVA has a bullish consensus with a median price target of $31.00 (ranging from $24.00 to $40.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $23.43, the median forecast implies a 32.3% upside. This outlook is supported by 18 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Andrew Mok at Barclays, suggesting a 2.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRVA Analyst Ratings
18
Buy
2
Hold
0
Sell
PRVA Price Target Range
Low
$24.00
Average
$31.00
High
$40.00
Current: $23.43
Latest PRVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 26, 2026 | Barclays | Andrew Mok | Equal-Weight | Maintains | $24.00 |
| May 8, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Apr 8, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Mar 25, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| Mar 3, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Mar 2, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Feb 27, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jan 9, 2026 | RBC Capital | Ryan Halsted | Outperform | Reinstates | $31.00 |
| Dec 4, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Nov 13, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Nov 13, 2025 | BMO Capital | Outperform | Initiates | $N/A | |
| Nov 12, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 10, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| Nov 10, 2025 | Truist Securities | Buy | Reiterates | $N/A | |
| Nov 7, 2025 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Nov 7, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Oct 9, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| Sep 24, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Sep 4, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Aug 29, 2025 | JMP Securities | Market Outperform | Maintains | $N/A |
Privia Health Group, Inc. (PRVA) Competitors
The following stocks are similar to Privia Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PRVA
Privia Health
mkt cap
2.95B
Privia Health Group, Inc. (PRVA) Financial Data
Privia Health Group, Inc. has a market capitalization of $2.95B with a P/E ratio of 137.8x. The company generates $2.25B in trailing twelve-month revenue with a 1.0% profit margin.
Revenue growth is +25.8% quarter-over-quarter, while maintaining an operating margin of +1.2% and return on equity of +3.6%.
Valuation Metrics
Market Cap
$2.95B
Enterprise Value
$2.59B
P/E Ratio
137.8x
PEG Ratio
-4.1x
Price/Sales
1.3x
Growth & Margins
Revenue Growth (YoY)
+25.8%
Gross Margin
+10.0%
Operating Margin
+1.2%
Net Margin
+1.0%
EPS Growth
-27.4%
Financial Health
Cash/Price Ratio
+14.2%
Current Ratio
1.6x
Debt/Equity
1.1x
ROE
+3.6%
ROA
+1.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Privia Health Group, Inc. (PRVA) Business Model
About Privia Health Group, Inc.
What They Do
Technology-driven physician enablement company.
Business Model
The company collaborates with physician practices, health plans, and health systems to optimize workflows and enhance patient experiences. It generates revenue by providing a comprehensive platform that includes technology and population health tools, streamlining operations for providers, and managing accountable care organizations. This model focuses on reducing administrative burdens and improving care coordination, ultimately advancing value-based care across various insurance programs.
Additional Information
Founded in 2007 and headquartered in Arlington, Virginia, the company emphasizes a physician-led governance structure and cloud-based solutions. Privia Health aims to empower independent practices by allowing them to focus on clinical excellence while improving their connection with payers and expanding patient populations.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
1,226
CEO
Mr. Parth Mehrotra
Country
United States
IPO Year
2021
Website
www.priviahealth.comPrivia Health Group, Inc. (PRVA) Latest News & Analysis
Latest News
Quick Summary
CEO Parth Mehrotra sold 121,086 shares for ~$2.73 million at $22.56 each, reducing his holdings by 21.80% to 434,357 shares as of May 12, 2026.
Why It Matters
CEO Parth Mehrotra's sale of 21.80% of his shares may signal a lack of confidence in the company's near-term prospects, potentially affecting investor sentiment and stock performance.
Source: The Motley Fool
Market Sentiment:
Neutral
Cross Keys Capital Advises Neurology Group of Bergen County in Its Partnership with Privia Health
17 days ago
Quick Summary
Cross Keys Capital advised the Neurology Group of Bergen County in its partnership with Privia Health. NGBC is a respected neurology practice in Bergen County, NJ, founded in 1973.
Why It Matters
The partnership between NGBC and Privia Health indicates consolidation in the healthcare sector, potentially enhancing market competitiveness and impacting stock valuations of involved companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Privia Health Enters New Jersey
18 days ago
Quick Summary
Privia Health Group (Nasdaq: PRVA) has signed a definitive agreement to expand into New Jersey by partnering with Neurology Group of Bergen County, which has 25 clinicians.
Why It Matters
Privia Health's expansion into New Jersey via partnership with NGBC signals growth potential, increased market share, and diversification, which could enhance revenue and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors in the Medical Info Systems sector may consider TruBridge (TBRG) and Privia Health (PRVA) as potential stock options for value opportunities.
Why It Matters
The excerpt highlights two potential investment opportunities in the Medical Info Systems sector, prompting investors to evaluate which stock offers better value.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Investors are comparing TruBridge (TBRG) and Privia Health (PRVA) for potential value opportunities in Medical Info Systems stocks.
Why It Matters
The comparison between TruBridge and Privia Health highlights potential investment opportunities, signaling investors to evaluate value propositions and make informed decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Privia Health Group Q1 Earnings Call Highlights
1 month ago
Quick Summary
Privia Health Group (NASDAQ: PRVA) reported strong Q1 results, highlighting double-digit provider growth, an increased value-based care population, and margin expansion.
Why It Matters
Privia Health's strong Q1 results, marked by provider growth and margin expansion, signal robust operational efficiency and potential for future profitability, attracting investor interest.
Source: MarketBeat
Market Sentiment:
Positive
Frequently Asked Questions About PRVA Stock
What is Privia Health Group, Inc.'s (PRVA) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Privia Health Group, Inc. (PRVA) has a median price target of $31.00. The highest price target is $40.00 and the lowest is $24.00.
Is PRVA stock a good investment in 2026?
According to current analyst ratings, PRVA has 18 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $23.43. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRVA stock?
Wall Street analysts predict PRVA stock could reach $31.00 in the next 12 months. This represents a 32.3% increase from the current price of $23.43. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Privia Health Group, Inc.'s business model?
The company collaborates with physician practices, health plans, and health systems to optimize workflows and enhance patient experiences. It generates revenue by providing a comprehensive platform that includes technology and population health tools, streamlining operations for providers, and managing accountable care organizations. This model focuses on reducing administrative burdens and improving care coordination, ultimately advancing value-based care across various insurance programs.
What is the highest forecasted price for PRVA Privia Health Group, Inc.?
The highest price target for PRVA is $40.00 from at , which represents a 70.7% increase from the current price of $23.43.
What is the lowest forecasted price for PRVA Privia Health Group, Inc.?
The lowest price target for PRVA is $24.00 from Andrew Mok at Barclays, which represents a 2.4% increase from the current price of $23.43.
What is the overall PRVA consensus from analysts for Privia Health Group, Inc.?
The overall analyst consensus for PRVA is bullish. Out of 4 Wall Street analysts, 18 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $31.00.
How accurate are PRVA stock price projections?
Stock price projections, including those for Privia Health Group, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 10:19 AM UTC